Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05173987
Title Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

uterine carcinosarcoma

endometrial carcinoma

Therapies

Cisplatin + Docetaxel

Carboplatin + Docetaxel

Carboplatin + Paclitaxel

Cisplatin + Paclitaxel

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | CAN

Additional content available in CKB BOOST